Cannabidiol, among other cannabinoid drugs, modulates prepulse inhibition of startle in the SHR animal model: implications for schizophrenia pharmacotherapy

Cannabidiol, among other cannabinoid drugs, modulates prepulse inhibition of startle in the SHR animal model: implications for schizophrenia pharmacotherapy

Schizophrenia is a severe psychiatric disorder that involves positive, negative and cognitive symptoms. Prepulse inhibition of startle reflex (PPI) is a paradigm that assesses the sensorimotor gating functioning and is impaired in schizophrenia patients as well as in animal models of this disorder....

Full description

Bibliographic Details
Main Authors: Fernanda Fiel Peres, Raquel Levin, Valéria Almeida, Antonio Waldo Zuardi, Jaime E Hallak, José Alexandre Crippa, Vanessa Costhek Abilio
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-09-01
Series:Frontiers in Pharmacology
Subjects:
Cannabidiol
Schizophrenia
Animal Models
prepulse inhibition
endocannabinoid system
cannabinoid drugs
Online Access:http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00303/full
Description
Summary:Schizophrenia is a severe psychiatric disorder that involves positive, negative and cognitive symptoms. Prepulse inhibition of startle reflex (PPI) is a paradigm that assesses the sensorimotor gating functioning and is impaired in schizophrenia patients as well as in animal models of this disorder. Recent data point to the participation of the endocannabinoid system in the pathophysiology and pharmacotherapy of schizophrenia. Here, we focus on the effects of cannabinoid drugs on the PPI deficit of animal models of schizophrenia, with greater focus on the SHR (Spontaneously Hypertensive Rats) strain, and on the future prospects resulting from these findings.
ISSN:1663-9812

Similar Items